# 510K SUMMARY

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92

The assigned 510(k) number is: K103656

# Company/Contact person

Lisa Charter   
Manager, Regulatory Affairs   
Thermo Fisher Scientific, Clinical Diagnostic Division   
46360 Fremont Blvd   
Fremont, CA 94538   
Phone: (510) 979-5142   
Facsimile: (510) 979-5422   
Email: Lisa.Charter@ThermoFisher.com

# Date Prepared

February 10, 2011

# Regulatory Declarations

<table><tr><td rowspan=1 colspan=1>Common / Usual Name</td><td rowspan=1 colspan=1>MAS® DOA Total</td></tr><tr><td rowspan=1 colspan=1>Trade/ Proprietary Name</td><td rowspan=1 colspan=1>Thermo Scientific MAS® DOA Total</td></tr><tr><td rowspan=1 colspan=1>Classification Regulation</td><td rowspan=1 colspan=1>21 CFR 862.3280</td></tr><tr><td rowspan=1 colspan=1>Device Class</td><td rowspan=1 colspan=1>Class I</td></tr><tr><td rowspan=1 colspan=1>Device Regulation Panel</td><td rowspan=1 colspan=1>Toxicology</td></tr><tr><td rowspan=1 colspan=1>Product Code</td><td rowspan=1 colspan=1>DIF</td></tr></table>

# Intended use

$M A S ^ { \oplus } D O A$ Total is intended for use as an assayed control for monitoring assay conditions in semi-quantitative and qualitative analysis of patient urine specimens for drugs and drug metabolites. These controls are human urine based and are composed of d-methamphetamine, secobarbital, nitrazepam, oxazepam, buprenorphine, benzoylecgonine, cotinine, ethyl glucuronide, ethanol, LSD, methadone, EDDP, methaqualone, morphine, oxycodone, phencyclidine, propoxyphene, nortriptyline, and L- $\cdot \Delta$ -9-THC-COOH.

MAS® DOA Total provides an estimation of the precision of a device test system and to detect and monitor systematic deviations from accuracy resulting from reagent or instrument defects.

# Legally marketed device to which equivalency is claimed

MAS® DOA Total is substantially equivalent to the previously cleared MAS DOA-XSE (K971058) and MGC DAU Control Sets: Primary, Clinical, and Select (K040758).

Description of Device

DOA TOTAL is prepared from certified drug free human urine pools. Analyte levels are adjusted with purified drugs or drug metabolites. Preservatives and stabilizers are added to maintain product integrity.

DOA TOTAL offers levels of controls, at concentrations $2 5 \%$ below and $2 5 \%$ above the screening cutoff levels used by the United States Department of Health and Human Services Substance Abuse and Mental Health Services Administration (SAMHSA); for Amphetamines, PCP (Phencyclidine), Opiates, Cocaine and Marijuana (Cannabinoid).   

<table><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>L1</td><td rowspan=1 colspan=1>L2</td><td rowspan=1 colspan=1>L3</td><td rowspan=1 colspan=1>L4</td><td rowspan=1 colspan=1>L5</td><td rowspan=1 colspan=1>L6</td><td rowspan=1 colspan=1>Concentration</td></tr><tr><td rowspan=1 colspan=1>d-Methamphetamine</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>750</td><td rowspan=1 colspan=1>1250</td><td rowspan=1 colspan=1>375</td><td rowspan=1 colspan=1>625</td><td rowspan=1 colspan=1>2000</td><td rowspan=1 colspan=1>ng/ml</td></tr><tr><td rowspan=1 colspan=1>Secobarbital</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>225</td><td rowspan=1 colspan=1>375</td><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>250</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>ng/mL</td></tr><tr><td rowspan=1 colspan=1>Nitrazepam</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>225</td><td rowspan=1 colspan=1>375</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>ng/mL</td></tr><tr><td rowspan=1 colspan=1>Oxazepam</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>250</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>ng/mL</td></tr><tr><td rowspan=1 colspan=1>Buprenorphine</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>ng/mL</td></tr><tr><td rowspan=1 colspan=1>Benzoylecgonine</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>225</td><td rowspan=1 colspan=1>375</td><td rowspan=1 colspan=1>112</td><td rowspan=1 colspan=1>118</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>ng/mL</td></tr><tr><td rowspan=1 colspan=1>Cotinine</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>375</td><td rowspan=1 colspan=1>625</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>ng/ml  &#x27;</td></tr><tr><td rowspan=1 colspan=1>ETG</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>375</td><td rowspan=1 colspan=1>625</td><td rowspan=1 colspan=1>750</td><td rowspan=1 colspan=1>1250</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>ng/mL</td></tr><tr><td rowspan=1 colspan=1>Ethanol</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>70</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>mg/dL</td></tr><tr><td rowspan=1 colspan=1>LSD</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>ng/mL</td></tr><tr><td rowspan=1 colspan=1>Methadone</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>225</td><td rowspan=1 colspan=1>375</td><td rowspan=1 colspan=1>225</td><td rowspan=1 colspan=1>375</td><td rowspan=1 colspan=1>750</td><td rowspan=1 colspan=1>ng/mL</td></tr><tr><td rowspan=1 colspan=1>EDDP</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>125</td><td rowspan=1 colspan=1>750</td><td rowspan=1 colspan=1>1250</td><td rowspan=1 colspan=1>1500</td><td rowspan=1 colspan=1>ng/mL</td></tr><tr><td rowspan=1 colspan=1>Methaqualone</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>225</td><td rowspan=1 colspan=1>375</td><td rowspan=1 colspan=1>225</td><td rowspan=1 colspan=1>375</td><td rowspan=1 colspan=1>750</td><td rowspan=1 colspan=1>ng/mL</td></tr><tr><td rowspan=1 colspan=1>Morphine</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>225</td><td rowspan=1 colspan=1>375</td><td rowspan=1 colspan=1>1500</td><td rowspan=1 colspan=1>2500</td><td rowspan=1 colspan=1>750</td><td rowspan=1 colspan=1>ng/mL</td></tr><tr><td rowspan=1 colspan=1>Oxycodone</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>125</td><td rowspan=1 colspan=1>225</td><td rowspan=1 colspan=1>375</td><td rowspan=1 colspan=1>750</td><td rowspan=1 colspan=1>ng/mL</td></tr><tr><td rowspan=1 colspan=1>PCP</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>ng/mL</td></tr><tr><td rowspan=1 colspan=1>PPX</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>225</td><td rowspan=1 colspan=1>375</td><td rowspan=1 colspan=1>225</td><td rowspan=1 colspan=1>375</td><td rowspan=1 colspan=1>750</td><td rowspan=1 colspan=1>ng/mL</td></tr><tr><td rowspan=1 colspan=1>Nortriptyline</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>185</td><td rowspan=1 colspan=1>415</td><td rowspan=1 colspan=1>750</td><td rowspan=1 colspan=1>1250</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>ng/mL</td></tr><tr><td rowspan=1 colspan=1>L-Δ-9-THC-COOH</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>38</td><td rowspan=1 colspan=1>62</td><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>ng/mL</td></tr></table>

# Summary of Clinical Testing

<table><tr><td rowspan=1 colspan=1>EvaluationParameter</td><td rowspan=1 colspan=1>AcceptanceCriteria</td><td rowspan=1 colspan=1>Specification</td><td rowspan=1 colspan=1>Pass /Fail</td></tr><tr><td rowspan=1 colspan=1>Target achievement</td><td rowspan=1 colspan=1>Analyteconcentrationsmeetspecification</td><td rowspan=1 colspan=1>L1: NegativeL2 -L6: recovery difference vs.target within +/-10%, except LSDwhich is within +/-15%</td><td rowspan=1 colspan=1>Pass</td></tr><tr><td rowspan=1 colspan=1>Open Bottle Stabilityat 5°</td><td rowspan=1 colspan=1>30 days</td><td rowspan=1 colspan=1>L1: NegativeL2-L6: recovery change within +/-10%</td><td rowspan=1 colspan=1>Pass</td></tr><tr><td rowspan=1 colspan=1>Close Bottle Stability- Product Shelf Life(5°C)</td><td rowspan=1 colspan=1>24 months(predicted)</td><td rowspan=1 colspan=1>L1: NegativeL2-L5: recovery change within +/-15%L6: recovery change within +/-20%</td><td rowspan=1 colspan=1>Pass</td></tr></table>

# Conclusion

As summarized, the MAS® DOA Total is substantially equivalent to previously cleared MAS DOA-XSE and MGC DAU Control Sets: Primary, Clinical, and Select. Substantial equivalence has been demonstrated through performance testing to verify that the device functions as intended and that design specifications have been satisfied.

Microgenics Corporation   
Thermo Fisher Scientific, Clinical Diagnostics Division c/o Ms. Lisa Charter   
Manager, Regulatory Affairs   
46360 Fremont Blvd.   
Fremont, CA 94538-6406

Re: k103656 Trade Name: Thermo Scientific MAS R DOA Total Regulation Number: 21 CFR $\ S 8 6 2 . 3 2 8 0$ EP Regulation Name: Clinical toxicology control material. Regulatory Class: Class I, reserved Product Codes: DIF Dated: February 10, 2011 Received: February 14, 2011

Dear Ms. Charter:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including. but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2 -

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796- 5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

GC.

Courthey Harper, Ph.D.   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

# Indications for Use

# 510(k) Number (if known): K103656

Device Name: Thermo Scientific MAS® DOA Total

# Indication for Use:

MAS® DOA Total is intended for use as an assayed control for monitoring assay conditions in semi-quantitative and qualitative analysis of patient urine specimens for drugs and drug metabolites. These controls are human urine based and are composed of d-methamphetamine, secobarbital, nitrazepam, oxazepam, buprenorphine, benzoylecgonine, cotinine, ethyl glucuronide, ethanol, LSD, methadone, EDDP, methaqualone, morphine, oxycodone, phencyclidine, propoxyphene, nortriptyline, and L-Δ-9-THC-COOH.

$M A S ^ { \otimes }$ DOA Total provides an estimation of the precision of a device test system and to detect and monitor systematic deviations from accuracy resulting from reagent or instrument defects.

Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

![](images/b360877363acb0b6edd3aa38cecb18ff95dfe1cd116bbe38795fac5e7daa13be.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety

510(k) K103656